JPT1: A Potential Drug Target and Biomarker for Jupiter Microtubule-Associated Homolog 1 (ISO Form 3)

Target Name: JPT1

NCBI ID: G51155

JPT1: A Potential Drug Target and Biomarker for Jupiter Microtubule-Associated Homolog 1 (ISO Form 3)

Introduction

Jupiter microtubule-associated homolog 1 (ISO Form 3) (JPT1) is a protein that plays a crucial role in the structure and function of microtubules in eukaryotic cells. Microtubules are dynamic cytoskeletal filaments that mediate cell division, intracellular transport, and mechanical forces. They are composed of a highly repetitive series of protein filaments that can be assembled and disassembled at various points along their length. JPT1 is one of the key proteins that forms the core of microtubules and is involved in their stability, dynamics, and regulation.

The JPT1 protein is composed of 115 amino acid residues and has a calculated molecular weight of 13.9 kDa. It is localized to the cytoskeleton and is involved in the organization and dynamics of microtubules. JPT1 is a member of the digital transformation tubulin family, which includes several other proteins that play a role in the structure and function of microtubules.

JPT1 is involved in the regulation of microtubule dynamics and stability. It is known to interact with several other microtubule-associated proteins, including microtubule protein 2 (MTAP), microtubule-associated protein 1 (MAP1), and tubulin protein. JPT1 is also known to interact with the microtubule-associated protein 2 (MAP2), which is a negative regulator of microtubule dynamics.

In addition to its role in microtubule dynamics, JPT1 is also involved in the regulation of cell division and the development of cancer. It has been shown to play a role in the regulation of mitosis and meiosis, which are processes that involve the division of cells . JPT1 has also been shown to be involved in the regulation of cell survival and the response to chemotherapy.

As a potential drug target, JPT1 has been identified as a potential target for small molecule inhibitors. Several studies have shown that inhibitors of JPT1 have the potential to disrupt microtubule dynamics and inhibit cell division. These inhibitors have been shown to have both therapeutic and toxic effects, depending on the specific context in which they are used.

In addition to its potential as a drug target, JPT1 has also been identified as a potential biomarker for several types of cancer. Its involvement in the regulation of microtubule dynamics and cell division makes it an attractive candidate for the development of biomarkers for cancer. Several studies have shown that the expression of JPT1 is altered in various types of cancer, including breast, lung, and ovarian cancer. These changes in JPT1 expression have been associated with poor prognosis and poor clinical outcomes in cancer patients.

Conclusion

Jupiter microtubule-associated homolog 1 (ISO Form 3) (JPT1) is a protein that plays a crucial role in the structure and function of microtubules in eukaryotic cells. It is involved in the regulation of microtubule dynamics and stability and is a potential drug target and biomarker for several types of cancer. The regulation of microtubule dynamics by JPT1 is complex and involves multiple interactions with other microtubule-associated proteins. Further research is needed to fully understand the role of JPT1 in microtubule regulation and its potential as a drug target and biomarker for cancer.

Protein Name: Jupiter Microtubule Associated Homolog 1

Functions: Modulates negatively AKT-mediated GSK3B signaling (PubMed:21323578, PubMed:22155408). Induces CTNNB1 'Ser-33' phosphorylation and degradation through the suppression of the inhibitory 'Ser-9' phosphorylation of GSK3B, which represses the function of the APC:CTNNB1:GSK3B complex and the interaction with CDH1/E-cadherin in adherent junctions (PubMed:25169422). Plays a role in the regulation of cell cycle and cell adhesion (PubMed:25169422, PubMed:25450365). Has an inhibitory role on AR-signaling pathway through the induction of receptor proteosomal degradation (PubMed:22155408)

More Common Targets